These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 4644648)

  • 21. Rx: Canadian drugs.
    Rawson NS
    N Engl J Med; 2004 Mar; 350(11):1155. PubMed ID: 15017685
    [No Abstract]   [Full Text] [Related]  

  • 22. Comparison of bioavailabilities and dissolution characteristics of commercial tablet formulations of sulfamethizole.
    Mattok GL; McGilveray IJ
    J Pharm Sci; 1972 May; 61(5):746-9. PubMed ID: 5035783
    [No Abstract]   [Full Text] [Related]  

  • 23. [Drug dosage form and action].
    Zathurecký L
    Med Klin; 1974 Apr; 69(16):667-70. PubMed ID: 4837397
    [No Abstract]   [Full Text] [Related]  

  • 24. Enforcement of the current good manufacturing practices for solid oral dosage forms after United States v. Barr Laboratories.
    Jimenez FA
    Food Drug Law J; 1997; 52(1):67-82. PubMed ID: 10346711
    [No Abstract]   [Full Text] [Related]  

  • 25. [Distribution and kinetics of nitrofurantoin in early pregnancy].
    Amon K; Amon I; Hüller H
    Int J Clin Pharmacol; 1972 Aug; 6(3):218-22. PubMed ID: 4648465
    [No Abstract]   [Full Text] [Related]  

  • 26. The official compendia.
    Macek TJ
    Pharmacology; 1972; 8(1):204-6. PubMed ID: 4644650
    [No Abstract]   [Full Text] [Related]  

  • 27. 3. Drug regulations in Switzerland and their application.
    Hippenmeier F
    Bull Parenter Drug Assoc; 1974; 28(4):167-73. PubMed ID: 4855448
    [No Abstract]   [Full Text] [Related]  

  • 28. Some factors affecting bioavailability of drug products.
    Lach JL
    J Iowa Med Soc; 1972 Aug; 62(8):441-2 passim. PubMed ID: 5044776
    [No Abstract]   [Full Text] [Related]  

  • 29. [The consequence of the preparation factors for the effect of the drug].
    Johnsgård M; Pedersen AO
    Tidsskr Nor Laegeforen; 1973 Apr; 93(10):698-703. PubMed ID: 4755086
    [No Abstract]   [Full Text] [Related]  

  • 30. [Standards imposed by the pharmacopoeia on drugs].
    Büchi J
    Pharm Acta Helv; 1972; 47(11):648-63. PubMed ID: 4657534
    [No Abstract]   [Full Text] [Related]  

  • 31. Bioavailability studies of acetaminophen and nitrofurantoin.
    Albert KS; Sedman AJ; Wilkinson P; Stoll RG; Murray WJ; Wagner JG
    J Clin Pharmacol; 1974; 14(5-6):264-70. PubMed ID: 4829520
    [No Abstract]   [Full Text] [Related]  

  • 32. The physiologic availability of solid dosage forms of phenylbutazone. II. Correlation of in vivo physiologic availability and in vitro dissolution parameters.
    Withey RJ; Feng H; Cook D; Van Petten GR; Lettau HF
    J Clin Pharmacol New Drugs; 1971; 11(3):187-96. PubMed ID: 5211352
    [No Abstract]   [Full Text] [Related]  

  • 33. Nitrofurantoin, sulfamethizole and cephalexin urinary concentration in unequally functioning pyelonephritic kidneys.
    Sullivan JW; Bueschen AJ; Schlegel JU
    J Urol; 1975 Sep; 114(3):343-7. PubMed ID: 238048
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of food on nitrofurantoin absorption.
    Bates TR; Sequeira JA; Tembo AV
    Clin Pharmacol Ther; 1974 Jul; 16(1):63-8. PubMed ID: 4843238
    [No Abstract]   [Full Text] [Related]  

  • 35. Generic inequivalence--clinical observations.
    Prescott LF; Nimmo J
    Acta Pharmacol Toxicol (Copenh); 1971; 29 Suppl 3():288-303. PubMed ID: 5317801
    [No Abstract]   [Full Text] [Related]  

  • 36. Global perspective on specifications for biotechnology products--perspective from Japan.
    Hayakawa T
    Dev Biol Stand; 1997; 91():15-23. PubMed ID: 9413678
    [No Abstract]   [Full Text] [Related]  

  • 37. Biowaiver for Immediate and Modified Release Dosage forms Scientific summary of the CSPS workshop.
    Loebenberg R
    J Pharm Pharm Sci; 2020; 23():. PubMed ID: 32877636
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biopharmaceutics and applied pharmacy.
    Krówczyński L
    Pharmazie; 1971 Nov; 26(11):659. PubMed ID: 5154316
    [No Abstract]   [Full Text] [Related]  

  • 39. Development of specifications for biotechnology products--perspective from Europe.
    Trouvin JH
    Dev Biol Stand; 1997; 91():25-30. PubMed ID: 9413679
    [No Abstract]   [Full Text] [Related]  

  • 40. Biopharmaceutical assessment of phenylbutazone and indomethacin preparations.
    Turakka H; Airaksinen MM
    Ann Clin Res; 1974; 6(0):suppl 11:34-43. PubMed ID: 4855463
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.